Almirall Crescita futura
Criteri Future verificati 4/6
Almirall prevede che gli utili e i ricavi cresceranno rispettivamente di 28% e 8.4% all'anno. Si prevede che l'EPS crescerà di 22% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 10% in 3 anni.
Informazioni chiave
28.0%
Tasso di crescita degli utili
21.96%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 20.2% |
| Tasso di crescita dei ricavi | 8.4% |
| Rendimento futuro del capitale proprio | 10.02% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 14 May 2026 |
Aggiornamenti recenti sulla crescita futura
Articolo di analisi • Nov 13
Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...Articolo di analisi • Jul 29
The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...Recent updates
Aggiornamento della narrazione • Feb 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have nudged their price target on Almirall higher to €13.91 from €13.69, reflecting updated assumptions on revenue growth, profit margins and future P/E, despite a recent downgrade in stance from BNP Paribas. Analyst Commentary Analysts are sending mixed signals on Almirall, with a higher price target sitting alongside a more cautious rating.Aggiornamento della narrazione • Jan 19
ALM: Future Re-Rating Will Rely On Dermatology Pipeline And Execution
Analysts slightly trimmed their price target for Almirall to €13.69 from €13.86, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Almirall plans to start a phase III study in the first half of 2026 evaluating Lebrikizumab (Ebglyss) for nummular eczema.Aggiornamento della narrazione • Jan 05
ALM: Future Re-Rating Will Depend On Pipeline Execution And Ebglyss Ramp-Up
Narrative update on Almirall Analysts have raised their price target on Almirall to €14.50, citing what they see as a still-compelling valuation, along with expectations for Ebglyss ramp-up, upcoming clinical readouts, and potential in-licensing and M&A to support the mid-stage pipeline. Analyst Commentary Recent research points to a target price of €14.50 for Almirall, with the view that the shares still offer a compelling entry point despite a prior rebound in the stock.Aggiornamento della narrazione • Dec 17
ALM: Future Re-Rating Will Hinge On Ebglyss Uptake And Pipeline Delivery
Analysts have modestly raised their price target on Almirall to EUR 14.50, citing expectations for a continued valuation re-rating supported by the ramp up of Ebglyss, upcoming clinical readouts, and potential in-licensing and M&A to bolster the mid-stage pipeline. Analyst Commentary Analyst views on Almirall remain broadly positive, with recent coverage highlighting both upside drivers and execution risks as the company advances its dermatology portfolio.Articolo di analisi • Dec 08
Market Cool On Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 2.6x is worth a...Aggiornamento della narrazione • Dec 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have modestly raised their 12 month price target for Almirall to EUR 14.50, citing expectations that a continued re rating driven by Ebglyss ramp up, upcoming clinical readouts, and potential in licensing and M&A could support upside from current levels. Analyst Commentary Analysts note that Almirall's investment case is increasingly driven by visible growth levers in medical dermatology, but also caution that execution on product ramps and pipeline milestones will be critical to sustaining the recent share price rebound.Aggiornamento della narrazione • Nov 19
ALM: Pipeline Milestones And Product Launch Momentum Will Drive Re-Rating
Analysts have increased their price target for Almirall from €13.30 to €13.87. They cite a compelling valuation, strong pipeline prospects, and expectations for continued growth driven by product launches and strategic developments.Articolo di analisi • Nov 17
Almirall's (BME:ALM) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...Articolo di analisi • Nov 13
Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...Articolo di analisi • Aug 19
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Jul 29
The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...Nuova narrazione • Jul 22
European Demographics Will Drive Advancements In Dermatology Treatments
Strong specialty product launches and robust R&D pipeline are expected to drive growth, improve margins, and boost Almirall's market position in innovative dermatology.Articolo di analisi • May 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 44% Above Its Share Price
Key Insights The projected fair value for Almirall is €14.08 based on 2 Stage Free Cash Flow to Equity Current share...Articolo di analisi • Mar 27
Why We're Not Concerned About Almirall, S.A.'s (BME:ALM) Share Price
With a median price-to-sales (or "P/S") ratio of close to 2.2x in the Pharmaceuticals industry in Spain, you could be...Articolo di analisi • Mar 03
Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are
Almirall, S.A. ( BME:ALM ) recently posted some strong earnings, and the market responded positively. Our analysis...Articolo di analisi • Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Dec 10
Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Articolo di analisi • Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Almirall, S.A. ( BME:ALM ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to €8.52...Articolo di analisi • Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)
You may think that with a price-to-sales (or "P/S") ratio of 2x Almirall, S.A. ( BME:ALM ) is a stock worth checking...Articolo di analisi • Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Almirall fair value estimate is €18.31 Current share price of...Articolo di analisi • Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Articolo di analisi • Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Articolo di analisi • Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Key Insights Almirall's estimated fair value is €11.86 based on 2 Stage Free Cash Flow to Equity Almirall's €9.37 share...Articolo di analisi • Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?
Key Insights Almirall's estimated fair value is €11.37 based on 2 Stage Free Cash Flow to Equity Current share price of...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 1,486 | 157 | 231 | 323 | 9 |
| 12/31/2027 | 1,365 | 122 | 176 | 274 | 11 |
| 12/31/2026 | 1,230 | 85 | 133 | 238 | 11 |
| 3/31/2026 | 1,121 | 40 | 49 | 196 | N/A |
| 12/31/2025 | 1,115 | 46 | 37 | 174 | N/A |
| 9/30/2025 | 1,085 | 42 | 30 | 201 | N/A |
| 6/30/2025 | 1,054 | 21 | 24 | 152 | N/A |
| 3/31/2025 | 1,028 | 24 | 5 | 164 | N/A |
| 12/31/2024 | 991 | 10 | -1 | 161 | N/A |
| 9/30/2024 | 953 | -45 | -23 | 149 | N/A |
| 6/30/2024 | 932 | -35 | -115 | 103 | N/A |
| 3/31/2024 | 915 | -39 | -48 | 116 | N/A |
| 12/31/2023 | 899 | -38 | -66 | 93 | N/A |
| 9/30/2023 | 907 | 7 | -23 | 101 | N/A |
| 6/30/2023 | 898 | -11 | 23 | 156 | N/A |
| 3/31/2023 | 882 | -8 | 37 | 154 | N/A |
| 12/31/2022 | 879 | 4 | 39 | 155 | N/A |
| 9/30/2022 | 864 | 9 | 105 | 177 | N/A |
| 6/30/2022 | 856 | 29 | 98 | 180 | N/A |
| 3/31/2022 | 843 | -50 | 82 | 159 | N/A |
| 12/31/2021 | 837 | -41 | 163 | 234 | N/A |
| 9/30/2021 | 814 | -22 | 204 | 288 | N/A |
| 6/30/2021 | 809 | -11 | 145 | 196 | N/A |
| 3/31/2021 | 790 | 55 | 122 | 198 | N/A |
| 12/31/2020 | 814 | 74 | 36 | 113 | N/A |
| 9/30/2020 | 849 | 63 | 72 | 212 | N/A |
| 6/30/2020 | 872 | 86 | 49 | 194 | N/A |
| 3/31/2020 | 926 | 121 | 158 | 296 | N/A |
| 12/31/2019 | 911 | 106 | N/A | 276 | N/A |
| 9/30/2019 | 858 | 85 | N/A | 190 | N/A |
| 6/30/2019 | 884 | 88 | N/A | 181 | N/A |
| 3/31/2019 | 789 | 80 | N/A | 138 | N/A |
| 12/31/2018 | 811 | 78 | N/A | 143 | N/A |
| 9/30/2018 | 714 | -111 | N/A | 170 | N/A |
| 6/30/2018 | 730 | -179 | N/A | 133 | N/A |
| 3/31/2018 | 687 | -293 | N/A | 82 | N/A |
| 12/31/2017 | 677 | -304 | N/A | 6 | N/A |
| 9/30/2017 | 735 | -128 | N/A | -89 | N/A |
| 6/30/2017 | 755 | -78 | N/A | -13 | N/A |
| 3/31/2017 | 821 | 73 | N/A | 12 | N/A |
| 12/31/2016 | 822 | 75 | N/A | 105 | N/A |
| 9/30/2016 | 778 | 162 | N/A | 151 | N/A |
| 6/30/2016 | 743 | 154 | N/A | 122 | N/A |
| 3/31/2016 | 721 | 111 | N/A | 114 | N/A |
| 12/31/2015 | 738 | 132 | N/A | 171 | N/A |
| 9/30/2015 | 783 | 479 | N/A | 761 | N/A |
| 6/30/2015 | 802 | 488 | N/A | 748 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di ALM ( 28% all'anno) è superiore al tasso di risparmio ( 2.7% ).
Guadagni vs Mercato: Si prevede che gli utili di ALM ( 28% all'anno) cresceranno più rapidamente del mercato Spanish ( 11.6% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di ALM cresceranno in modo significativo nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di ALM ( 8.4% all'anno) crescerà più rapidamente del mercato Spanish ( 6.4% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di ALM ( 8.4% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di ALM sarà basso tra 3 anni ( 10 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 08:30 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Almirall, S.A. è coperta da 27 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |